Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Up 58.8% in July

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a significant growth in short interest in the month of July. As of July 31st, there was short interest totaling 425,882 shares, a growth of 58.8% from the July 15th total of 268,180 shares. Currently, 7.0% of the shares of the company are short sold. Based on an average daily trading volume, of 34,680 shares, the short-interest ratio is presently 12.3 days.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of XLO. BlackRock Inc. purchased a new position in Xilio Therapeutics in the second quarter valued at about $84,000. Jane Street Group LLC purchased a new position in Xilio Therapeutics during the fourth quarter valued at approximately $27,000. Velan Capital Investment Management LP bought a new position in shares of Xilio Therapeutics in the fourth quarter worth $109,000. State Street Corp increased its stake in Xilio Therapeutics by 13.7% in the 4th quarter. State Street Corp now owns 186,390 shares of the company’s stock worth $119,000 after acquiring an additional 22,500 shares during the last quarter. Finally, Stonepine Capital Management LLC raised its holdings in shares of Xilio Therapeutics by 252.2% in the 2nd quarter. Stonepine Capital Management LLC now owns 225,994 shares of the company’s stock valued at $2,165,023,000 after acquiring an additional 161,832 shares in the last quarter. Hedge funds and other institutional investors own 54.29% of the company’s stock.

Xilio Therapeutics Price Performance

NASDAQ XLO opened at $9.50 on Wednesday. The stock has a market capitalization of $62.51 million, a P/E ratio of -5.79 and a beta of -0.14. The business has a 50 day simple moving average of $8.97 and a 200 day simple moving average of $8.38. Xilio Therapeutics has a one year low of $6.47 and a one year high of $12.74.

Xilio Therapeutics (NASDAQ:XLO) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.26. Xilio Therapeutics had a negative net margin of 34.06% and a negative return on equity of 71.99%. The business had revenue of $18.69 million during the quarter, compared to analysts’ expectations of $12.72 million.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Weiss Ratings cut Xilio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 6th. Wall Street Zen lowered Xilio Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Xilio Therapeutics Company Profile

Xilio Therapeutics is a clinical?stage biotechnology company focused on the discovery and development of tumor?targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro?drug versions of potent immune?modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin?12 (IL?12) and interleukin?2 (IL?2) molecules fused to tumor?binding antibodies or peptide ligands.